You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 7,732,407

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,732,407

Title:	Method for treatment of demyelinating central nervous system disease
Abstract:	A method for treating demyelinating central nervous system diseases in a subject that comprises administering to the subject a composition comprising a therapeutically active amount of colony stimulating factor or CSF-like ligand. In a preferred embodiment of the present invention, the CSF is a GM-CSF. In a most preferred embodiment of the present invention, CSF is sargramostim.
Inventor(s):	Hunter; Samuel F. (Franklin, TN)
Assignee:
Application Number:	11/467,088
Patent Claims:	1. A method for treating demyelinating central nervous system diseases in a subject, comprising: determining the presence of neural demyelination in a subject; and administering to a subject in need thereof a composition comprising an effective demyelination-inhibiting amount of a granulocyte-macrophage colony stimulating factor. 2. The method of claim 1 wherein the origin of said colony stimulating factor is natural, recombinant, or chemically synthesized. 3. The method of claim 1 wherein said colony stimulating factor is delivered orally, or parenterally. 4. The method of claim 1 wherein said colony stimulating factor is administered by a therapeutically effective means chosen from transmucosal, subcutaneous, transcutaneous, intramuscular, intravenous, or implantation of sustained release formulations. 5. The method of claim 1, wherein said colony stimulating factor ligand is sargramostim. 6. The method of claim 1, wherein said colony stimulating factor is administered to the subject in an amount of from about 50 to about 250 micrograms. 7. The method of claim 1, wherein said method comprises administering to the subject at least one of an antibiotic, sulfonamide, anti-inflammatory agent, or an immunomodulatory agent. 8. The method of claim 1, wherein said disease is inflammatory phase multiple sclerosis. 9. The method of claim 1, wherein said disease has at least one of the following manifestations: acute, chronic, single episode, recurrent episode, progressive, progressive-relapsing, relapsing-progressive, and unremitting. 10. The method of claim 1 wherein said composition includes a type 1 interferon. 11. The method of claim 10 wherein said type 1 interferon includes an interferon beta. 12. The method of claim 11 wherein said interferon beta includes interferon-beta-1a. 13. A method of treating multiple sclerosis comprising: determining the presence of neural demyelination in a subject; and administering to a subject in need thereof a composition comprising an effective demyelination-inhibiting amount of a granulocyte-macrophage colony stimulating factor. 14. The method of claim 13 wherein the origin of said colony stimulating factor is natural, recombinant, or chemically synthesized. 15. The method of claim 13 wherein said colony stimulating factor-like ligand is delivered orally, or parenterally. 16. The method of claim 13, wherein said colony stimulating factor is sargramostim. 17. The method of claim 13, wherein said colony stimulating factor is administered to the subject in an amount of from about 50 to about 250 micrograms. 18. The method of claim 13, wherein said method comprises administering to the subject at least one of an antibiotic, sulfonamide, anti-inflammatory agent, or an immunomodulatory agent. 19. The method of claim 13 wherein said composition includes a type 1 interferon. 20. The method of claim 19 wherein said type 1 interferon includes an interferon beta. 21. A method of improving demyelinating central nervous system disease treatment in a subject, comprising: determining the presence of neural demyelination in a subject; and administering to a subject in need thereof a composition comprising an effective demyelination-inhibiting amount of a granulocyte-macrophage colony stimulating factor. 22. The method of claim 21 wherein said colony stimulating factor is delivered orally, or parenterally. 23. The method of claim 21 wherein said colony stimulating factor is sargramostim. 24. The method of claim 21, wherein said method comprises administering to the subject at least one of an antibiotic, sulfonamide, anti-inflammatory agent, or an immunomodulatory agent.

Details for Patent 7,732,407

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991	⤷ Try a Trial	2039-02-26
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.